MedTrace Logo

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1003

Last updated 2016-09-27

No results posted yet for this study

Summary

The purpose of this study is to determine if Dimebon is safe and effective in patients with mild to moderate Alzheimer's disease on Donepezil.

Conditions

Interventions

DRUG

Dimebon

5 mg orally three times daily

DRUG

Dimebon

20 mg orally three times daily

DRUG

Placebo comparator

Placebo orally three times daily

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Medivation, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • United States
  • Australia
  • Belgium
  • Finland
  • France
  • Germany
  • Italy
  • New Zealand
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00829374 on ClinicalTrials.gov